"Thienamycins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Beta-lactam antibiotics that differ from PENICILLINS in having the thiazolidine sulfur atom replaced by carbon, the sulfur then becoming the first atom in the side chain. They are unstable chemically, but have a very broad antibacterial spectrum. Thienamycin and its more stable derivatives are proposed for use in combinations with enzyme inhibitors.
| Descriptor ID |
D013845
|
| MeSH Number(s) |
D02.065.589.099.124.300 D03.633.100.300.124.300
|
| Concept/Terms |
Thienamycins- Thienamycins
- Antibiotics, Thienamycin
- Thienamycin Antibiotics
|
Below are MeSH descriptors whose meaning is more general than "Thienamycins".
Below are MeSH descriptors whose meaning is more specific than "Thienamycins".
This graph shows the total number of publications written about "Thienamycins" by people in this website by year, and whether "Thienamycins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 1 | 2 |
| 2016 | 2 | 1 | 3 |
| 2017 | 10 | 12 | 22 |
| 2018 | 9 | 1 | 10 |
To return to the timeline, click here.
Below are the most recent publications written about "Thienamycins" by people in Profiles.
-
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. JAMA. 2018 09 11; 320(10):984-994.
-
Molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa in an endemic area: comparison with global data. Eur J Clin Microbiol Infect Dis. 2018 Jul; 37(7):1211-1220.
-
Nephrotoxicity of piperacillin/tazobactam combined with vancomycin: should it be a concern? Int J Antimicrob Agents. 2018 Aug; 52(2):180-184.
-
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. JAMA. 2018 02 27; 319(8):788-799.
-
Meropenem time above the MIC exposure is predictive of response in cystic fibrosis children with acute pulmonary exacerbations. Diagn Microbiol Infect Dis. 2018 Jul; 91(3):294-297.
-
Differences in the rate of carbapenem-resistant Enterobacteriaceae colonisation or Clostridium difficile infection following frontline treatment with tigecycline vs. meropenem for intra-abdominal infections. Int J Antimicrob Agents. 2018 Mar; 51(3):516-521.
-
Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study. Crit Care. 2018 01 30; 22(1):25.
-
Pharmacokinetics of high-dose extended-infusion meropenem during pulmonary exacerbation in adult cystic fibrosis patients: a case series. New Microbiol. 2018 Jan; 41(1):47-51.
-
Development and validation of an LC tandem MS assay for the quantification of ß-lactam antibiotics in the sputum of cystic fibrosis patients. J Antimicrob Chemother. 2018 Jan 01; 73(1):95-101.
-
Maximally effective dosing regimens of meropenem in patients with septic shock. J Antimicrob Chemother. 2018 Jan 01; 73(1):191-198.